Cambridge, Mass. — Jan 22, 2025
Insilico Medicine, a biotechnology company leveraging generative artificial intelligence (AI) for drug discovery, has announced that the first patient has been dosed in the global multicenter Phase I clinical trial of ISM6331. This novel pan-TEAD inhibitor is being tested for the treatment of mesothelioma and other solid tumors. The trial, conducted in both China and the United States, marks a key milestone in the development of ISM6331 (NCT06566079).
Overview of the Phase I Trial
The Phase I trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ISM6331. It consists of two parts:
- A dose escalation phase, which began with the first patient enrolled in China.
- A dose optimization phase, which will follow.
Dr. Sujata Rao, Chief Medical Officer of Insilico Medicine, expressed optimism about the trial’s progress:
“We are pleased to announce the dosing of the first patient in our Phase I ISM6331 clinical trial in mesothelioma and other solid tumors. We are also accelerating patient enrollment in the U.S. to deliver innovative therapies that meet urgent medical needs.”
Key Features of ISM6331
ISM6331 is a pan-TEAD inhibitor designed to target the Hippo pathway, which regulates cancer cell proliferation and survival. By blocking the transcription of oncogenic genes, ISM6331 aims to halt tumor growth. Preclinical studies showed that ISM6331:
- Demonstrates broad anti-tumor efficacy.
- Enhances the effectiveness of combination therapies.
- Overcomes drug resistance.
Preclinical Success
In animal models, ISM6331:
- Exhibited potent anti-tumor effects at low doses.
- Maintained a favorable safety profile.
The compound’s structure was optimized using Insilico’s Chemistry42 AI platform, ensuring high efficacy and safety. These preclinical successes supported the transition to clinical testing.
Comments from Leadership
Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, remarked:
“By inhibiting TEAD, ISM6331 has the potential to suppress tumor growth, providing a targeted approach for cancers driven by the Hippo pathway. We are excited to move forward with further clinical validation and aim to translate these findings into clinical benefits for patients.”
About Insilico Medicine
Insilico Medicine is a pioneering AI-driven biotech company developing innovative therapeutics across a broad disease spectrum. Its proprietary platform integrates:
- Deep learning
- Generative modeling
- Reinforcement learning
The company’s pipeline includes therapies for cancer, fibrosis, central nervous system (CNS) disorders, and aging-related diseases.
For more information, visit:
By
